In May 2021, in a move to improve operational efficiency, Aurobindo Pharma had approved the transfer of its injectable assets into a subsidiary called Eugia Pharma Specialities Limited for “greater focus, attention and specialization” and also to “augment fund-raise and strategic tie-ups in future through joint ventures etc